Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02346955
Title Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications
Therapies
Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
Call for Information (Investigational Site 0003) Los Angeles California 90095 United States Details
Call for Information (Investigational Site 0004) New Haven Connecticut 06513 United States Details
Merck Sharp & Dohme Co. Ltd. Hod Hasharon Israel Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field